skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples

IgA vasculitis (Henoch–Shönlein purpura) in adults: Diagnostic and therapeutic aspects

Audemard-Verger, Alexandra ; Pillebout, Evangeline ; Guillevin, Loïc ; Thervet, Eric ; Terrier, Benjamin

Autoimmunity reviews, 2015-07, Vol.14 (7), p.579-585 [Periódico revisado por pares]

Elsevier B.V

Texto completo disponível

Citações Citado por
  • Título:
    IgA vasculitis (Henoch–Shönlein purpura) in adults: Diagnostic and therapeutic aspects
  • Autor: Audemard-Verger, Alexandra ; Pillebout, Evangeline ; Guillevin, Loïc ; Thervet, Eric ; Terrier, Benjamin
  • Assuntos: Allergy and Immunology ; Characteristics ; Henoch–Shönlein purpura ; IgA vasculitis ; Prognosis ; Treatment
  • É parte de: Autoimmunity reviews, 2015-07, Vol.14 (7), p.579-585
  • Descrição: Abstract Immunoglobulin A (IgA) vasculitis, formerly called Henoch–Schönlein purpura, is an immune complex vasculitis affecting small vessels with dominant IgA deposits. Clinical manifestations mainly involve cutaneous purpura, arthralgias and/or arthritis, acute enteritis and glomerulonephritis. IgA vasculitis is more common among children than adults, with more severe disease in adults. Gastrointestinal and renal involvements represent the principal causes of morbidity and mortality in adults. Factors associated with long-term end-stage renal disease (ESRD) include baseline renal function impairment and baseline proteinuria > 1 or 1.5 g/day, and on renal biopsy degree of interstitial fibrosis, sclerotic glomeruli and fibrinoid necrosis. Management of IgA vasculitis in adults is rendered difficult for clinicians because of the absence of correlation between initial presentation and long-term renal outcome, and the possible occurrence of spontaneous remission in patients with severe presentation or, in contrast, possible evolution to ESRD in patients with mild symptoms. Treatment is often symptomatic because disease course is usually benign. Treatment of severe involvement, including severe gastrointestinal complications or proliferative glomerulonephritis, remains controversial, with no evidence that corticosteroids or immunosuppressive agents improved long-term outcome. Prospective, randomized, controlled trials are thus needed to analyze the benefit–risk ratio of such treatments.
  • Editor: Elsevier B.V
  • Idioma: Inglês
Voltar para lista de resultados
Resultado  1 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.